GKOS - Glaukos Corporation
Corient Private Wealth LP acquired a new stake in Glaukos Corporation (NYSE: GKOS) during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 57,048 shares of the medical instruments supplier's stock, valued at approximately $7,973,000. Corient Private Wealth LP owned approximately 0.10% of Glaukos at the
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?
Algert Global LLC lessened its holdings in shares of Glaukos Corporation (NYSE: GKOS) by 43.0% in the second quarter, according to its most recent filing with the SEC. The firm owned 30,871 shares of the medical instruments supplier's stock after selling 23,330 shares during the quarter. Algert Global LLC owned about 0.05% of
Deutsche Bank AG acquired a new stake in Glaukos Corporation (NYSE: GKOS) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 61,957 shares of the medical instruments supplier's stock, valued at approximately $8,659,000. Deutsche Bank AG owned about 0.11% of Glaukos at the
Glaukos' iDose TR momentum and Epioxa launch are driving record growth, higher 2026 guidance and a broader ophthalmology platform.
Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 3:00 p.m. ET in Boston, MA. A live and archived webcast for these events, where applicable, will be available in the Investors.
Small-cap stocks are surging, but how you own them matters more than most investors realize.
First Trust Advisors LP increased its holdings in Glaukos Corporation (NYSE: GKOS) by 2,085.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,754 shares of the medical instruments supplier's stock after buying an additional 40,798 shares
GKOS' Q2 loss narrows as revenues jump 50% on iDose TR and Epioxa growth, lifting its 2026 sales outlook and shares by 9.8%.
Glaukos NYSE: GKOS reported record second-quarter 2026 consolidated net sales of $185.6 million, up 50% from the prior-year period on a reported basis and 49% on a constant-currency basis, as growth in its U.S. glaucoma, international glaucoma and corneal health businesses exceeded management's expectations.
Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Glaukos Corporation (GKOS) Q2 2026 Earnings Call Transcript
Glaukos (GKOS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.24 per share a year ago.
Glaukos Corporation remains rated "Hold" as shares approach technical resistance near $160 ahead of the Q2 earnings release. Strong revenue growth—41%+ in Q1 and 38% YoY in Q3—has driven recent upgrades and fueled a 91% stock rally since last year. Key catalysts include potential Q2 revenue outperformance, guidance hikes above $640 million, and robust uptake of Epioxa and iDose TR.
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the completion of patient enrollment in its U.S. 510(k) pivotal study evaluating the PRESERFLO™ MicroShunt in adult patients with primary open-angle glaucoma (POAG) who failed previous medical and surgical treatment. The PRESERFLO MicroShunt is a novel.
Bank of New York Mellon Corp reduced its stake in shares of Glaukos Corporation (NYSE: GKOS) by 3.6% during the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 343,173 shares of the medical instruments supplier's stock after selling 12,667 shares during the period. Bank of New
Alex R. Thurman generated ~$1.6 million in gross proceeds by selling 10,000 shares at $155 per share on July 9. The disposition represented 19% of the insider's total equity holdings, including shares acquired through a concurrent option exercise.
Abbott Laboratories offers a highly diversified healthcare portfolio with strong profitability across diagnostics and medical devices. Glaukos provides high-growth potential through its specialized focus on disruptive ophthalmic technologies for glaucoma and corneal care.
GKOS has surged nearly 45% since May-end as upbeat iDose TR commentary, strong sales and growth expectations lift investor confidence.